Executive Vice President, Chief Financial Officer and Treasurer · Y-mAbs Therapeutics, Inc. (YMAB)

Peter Pfreundschuh

FY2024 is the first fiscal year CompBrief holds for Peter Pfreundschuh as a named executive officer of Y-mAbs Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,504,717

Compensation figures as of the proxy filed May 30, 2025 (DEF 14A).

Peter Pfreundschuh compensation by year

Y-mAbs Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Y-mAbs Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$252,083
Bonus$0
Stock awards$573,620
Option awards$1,580,609
Non-equity incentive$98,405
Pension and deferred compensation$0
All other$0
Total$2,504,717

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Y-mAbs Therapeutics, Inc. DEF 14A filed May 30, 2025, accession 0001558370-25-008299, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU46,000$360,180—

Per the Outstanding Equity Awards at Fiscal Year-End table in Y-mAbs Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Y-mAbs Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Michael RossiPresident and Chief Executive Officer$4,557,590
Peter Pfreundschuh · this pageExecutive Vice President, Chief Financial Officer and Treasurer$2,504,717
Thomas GadFounder, Chief Business Officer and Vice Chairman of the Board of Directors$2,075,163

The full Y-mAbs Therapeutics compensation record

free company brief

This page is one person within Y-mAbs Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Y-mAbs Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Y-mAbs Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy